In regulatory news:

The FDA is alerting healthcare professionals not to administer to patients compounded or repackaged drugs that have been stored in 3- and 5-mL syringes manufactured by Becton Dickinson (BD) unless there is no suitable alternative available. Preliminary information indicates that drugs stored in these syringes may lose potency over time due to a possible interaction with the rubber stopper in the syringe. The agency has received several reports of compounded and repackaged drugs (such as fentanyl, morphine, methadone and atropine) losing potency when stored in BD 3- and 5-mL general-purpose syringes. It is possible that this chemical reaction may affect other compounded and repackaged drugs stored in syringes not FDA-cleared for closed container storage. 
Hospital and pharmacy staff should check supply stocks and remove drug products that were filled by pharmacies or outsourcing facilities and stored in general-purpose BD 3- and 5-mL syringes. These syringes are marked with the company logo at the base of the syringe.

Read more from Pain Medicine News here.

Leave a Comment

Your email address will not be published. Required fields are marked *